Carola Galbiati Selected Research

Septic Shock (Toxic Shock Syndrome)

11/2023	Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.
10/2023	High dose esomeprazole as an anti-inflammatory agent in sepsis: Protocol for a randomized controlled trial.
1/2021	Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carola Galbiati Research Topics

Disease

3	Sepsis (Septicemia) 11/2023 - 01/2021
3	Critical Illness (Critically Ill) 11/2023 - 01/2021
3	Septic Shock (Toxic Shock Syndrome) 11/2023 - 01/2021
2	Infections 10/2023 - 01/2021
1	Kidney Diseases (Kidney Disease) 10/2022

Drug/Important Bio-Agent (IBA)

2	Meropenem (Merrem)FDA LinkGeneric 11/2023 - 01/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2023 - 01/2021
1	Esomeprazole (Nexium)FDA Link 10/2023
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 10/2023
1	Proton Pump InhibitorsIBA 10/2023
1	Amino Acids FDA Link 10/2022
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2021
1	LactamsIBA 01/2021

Therapy/Procedure

2	Therapeutics 10/2023 - 01/2021
1	Length of Stay 10/2022